Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Biotech company Regeneron (NASDAQ:REGN) reported Q3 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $3.75 billion. Its non-GAAP profit of $11.83 per ...

Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.

Discover Regeneron’s Q3 2025 earnings: strong Dupixent, Libtayo & EYLEA HD growth, R&D updates, plus key manufacturing and regulatory challenges.

Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the ...

The FDA has issued another complete response letter (CRL) to Regeneron, rejecting its bid for approval of its prefilled syringe version of high-dose (HD) Eylea—again for unresolved issues at the ...

Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall ...

Yesterday, GSK added a new antibody-drug conjugate to its cancer pipeline via a $358 million agreement with French biotech ...

The chipmaker at the heart of the AI boom was one of the top performers in the S&P 500 Tuesday, helping push the index to an ...

Regeneron Pharmaceuticals (($REGN)) has held its Q3 earnings call. Read on for the main highlights of the call. Regeneron Pharmaceuticals’ recent ...